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ABSTRACT 50 
Background: Prior evidence suggests high-calcium intake influences postprandial appetite 51 
and insulinemia, possibly due to elevated incretins. In vitro and ex vivo models demonstrate 52 
extracellular calcium and protein synergistically enhance secretion of incretins. This is yet to 53 
be shown in humans. 54 
Objective: This study was designed to assess energy intake compensation in response to 55 
protein and calcium ingestion. 56 
Design: Twenty healthy adults (13 men; 7 women) completed 4 trials in a randomized 57 
double-blind, crossover design, separated by ≥ 48 h. During trials, participants consumed 58 
preloads which were low in protein and calcium (CON; 4 g and 104 mg, respectively), high 59 
in protein (PRO; 29 g), high in calcium (CAL; 1170 mg) or high in both protein and calcium 60 
(PROCAL). Blood samples were collected at baseline, and 15, 30, 45 and 60 min following 61 
preload ingestion, to determine insulin and incretin hormone concentrations. Energy intake 62 
was assessed by a homogenous test-meal 60 min after the preload. Visual analogue scales 63 
were completed immediately before blood sampling to assess subjective appetite sensations. 64 
Results: Relative to CON, PRO produced 100% (95% CI: 85, 115%) energy compensation, 65 
whereas CAL produced significant overcompensation 118% (95% CI: 104, 133%), which 66 
was significantly more positive than PRO (P < 0.05). PROCAL resulted in energy 67 
compensation of 109% (95% CI: 95, 123%), which tended to be greater than PRO (P = 0.06). 68 
The mean difference in appetite sensations relative to CON was not significantly different 69 
between PRO (-3; 95% CI: -8 to 3 mm), CAL (-5; 95% CI: -9 to 0) and PROCAL (-5; 95% 70 
CI: -10 to -1; P > 0.05). 71 
Conclusions: The addition of protein to a preload results in almost perfect energy 72 
compensation, whereas addition of calcium, with or without protein suppresses appetite and 73 
produces over compensation of subsequent energy intake. The role of circulating insulin and 74 
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incretin concentrations in these responses however, remain unclear. Registered at 75 
clinicaltrials.gov: NCT01986036. 76 
 77 
Keywords: females; food intake; fullness; glucagon-like peptide-1; hunger; insulin; males; 78 
protein. 79 
 80 
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INTRODUCTION 82 
Habitual calcium intake is inversely associated with body fat percentage (1) and randomised 83 
controlled trials indicate that this may be a causal relationship, ie. calcium (plus vitamin D) 84 
supplementation augments fat loss under energy restriction (2). Whilst a decrease in dietary 85 
fat absorption is likely to partially account for this (3), fat excretion (typically increased by 2 86 
g/d (3)) cannot account for the effect size typically reported in energy-restriction studies 87 
(equivalent to an additional ~5 g/d (2)). Thus, other mechanisms are likely to contribute. 88 
Some putative mechanisms include increased lipid utilization (4, 5) and reductions in ad 89 
libitum energy intake (6) and appetite sensations (7, 8). 90 
Previous research has indicated that a single high-calcium (plus vitamin D) meal may 91 
decrease subsequent self-reported 24 h food intake (6). However in this study, energy intake 92 
did not differ during the controlled (non-self-report), laboratory period. This lack of an effect 93 
with non-self report measures has been shown by others (9). It was only when participants 94 
provided self-reported food diaries for the subsequent 24 h that energy intake was lower with 95 
a high-calcium (plus vitamin D) breakfast (6). Therefore it remains to be determined whether 96 
calcium intake can influence acute food intake in humans, with precise measurement of 97 
energy intake.  98 
Notwithstanding this, we have previously reported that the addition of calcium to a 99 
mixed-macronutrient meal suppresses postprandial appetite sensations whilst concomitantly 100 
elevating insulinaemia (7, 8). These responses may be (in part) due to the gastrointestinal 101 
peptides, glucose-dependent insulinotropic polypeptide1-42 (GIP1-42; formerly known as 102 
gastric inhibitory peptide) and glucagon-like peptide-17-36 (GLP-17-36) (8). GIP1-42 and GLP-103 
17-36 are secreted by enteroendocrine cells in the gastrointestinal tract and are degraded by the 104 
enzyme dipeptidyl peptidase-IV (DPP-IV (10)). Evidence from both human embryonic 105 
kidney cells (11), and an isolated rodent intestinal model (12) suggest that the secretion of 106 
Page 6 
these peptides is elevated by stimulation of the extracellular calcium sensing receptor [present 107 
in the human gastrointestinal tract (13)] by an elevated extracellular/luminal calcium 108 
concentration. Moreover, this effect is potentiated by the presence of amino acids (11, 12). 109 
Taken in concert with the observation that milk peptides display DPP-IV inhibitory activity 110 
(14), the presence of protein and calcium in a meal may act synergistically to enhance plasma 111 
glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 concentrations. 112 
This may in turn, make a contribution to a reduction in appetite and improve energy intake 113 
compensation. 114 
Therefore, the primary aim of this study was to assess the effects of protein and 115 
calcium in a preload on subsequent compensation of energy intake. Secondary aims were to 116 
assess the subjective appetite, and plasma insulin, GIP1-42 and GLP-17-36 responses to the 117 
preloads. 118 
 119 
PARTICIPANTS AND METHODS 120 
Study design 121 
This study was a double-blind (both investigators and participants were blinded to the 122 
intervention), randomized crossover study consisting of 4 main trials, comprised of control 123 
(CON), high-calcium (CAL), high-protein (PRO) and high-protein and high-calcium 124 
(PROCAL) trials (registered on clinicaltrials.gov as NCT01986036). Each trial was separated 125 
by ≥ 2 d but ≤ 7 d. Trials were conducted in the nutrition and metabolism laboratories of 126 
Northumbria University (Newcastle-upon-Tyne, UK) in accordance with the Second 127 
Declaration of Helsinki, and following approval from the Northumbria University Faculty of 128 
Health and Life Sciences Ethics Committee. Random assignment (www.randomization.com), 129 
blinding, and the preparation of preload meals, was performed by PLS Rumbold, who had no 130 
further involvement in data acquisition.  131 
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 132 
Participants 133 
A sample size estimation was conducted based on the reported 9.3% difference in ad libitum 134 
energy intake following a single high-calcium meal vs. a low-calcium meal (6). Given that 135 
the day-to-day variation in this measure is 8.9% (15), it was estimated that 16 participants 136 
would provide more than an 80% chance of statistically detecting a difference with P < 0.05. 137 
In order to account for potential dropouts, following informed written consent, 20 participants 138 
(12 M, 8 F) were recruited from the Northumbria University student and staff population 139 
(characteristics displayed in Table 1) between October 2013 and January 2014. Inclusion 140 
criteria included a BMI between 18.5 and 29.9 kg/m2 and aged 18-40 y. Participants were 141 
excluded if they smoked, had any history of food allergies, metabolic disorders such as type 2 142 
diabetes or displayed dietary restraint (defined as a score of >13 on the Three-Factor Eating 143 
Questionnaire (16)). No direct male-female comparisons were made due to the difference in 144 
group sizes, however, for information in the homogeneity of the participants, their 145 
characteristics are provided as males alone, females alone, and the total group. 146 
 147 
Main trials 148 
Participants arrived in the laboratory at 0800 ± 1 h after an overnight fast (10-14 h) and 24 h 149 
of physical activity standardization. Participants were asked to refrain from alcohol and 150 
caffeine for 24 h, and to record and replicate their evening meal prior to trials. For all female 151 
participants, all main trials were carried out during the early follicular phase of the menstrual 152 
cycle (3-6 d following the first day of menses). An intravenous catheter was inserted into an 153 
antecubital vein and, following a baseline blood sample and visual analogue scale (VAS), 154 
participants consumed one of 4 preloads (CON, PRO, CAL, PROCAL). A timer was started 155 
when participants consumed the first mouthful of the preload, following which, blood 156 
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samples and VAS were taken at 15, 30, 45 and 60 min post-preload. Food intake was then 157 
assessed (60 min following preload ingestion) by providing participants with a homogenous 158 
pasta meal (as previously described (17)), which they were asked to consume until 159 
“comfortably full”. The mass of food consumed was then converted into energy intake taking 160 
into account water losses from reheating. The time frame following the preload was based on 161 
our previous findings where appetite sensations following a high-calcium breakfast were 162 
divergent within the first 60 min postprandial (7, 8). Participants were initially served a sub-163 
serving of the whole portion, which was augmented at regular intervals. This method 164 
prevents the overwhelming sensation of the whole portion of pasta, whilst never allowing the 165 
serving bowl to be empty and thus preventing the cessation of the eating occasion due to the 166 
end of a “portion”.  167 
 168 
Preloads 169 
All preloads contained instant porridge oats (Oatso Simple Golden Syrup, Quaker Oats UK, 170 
Leicester, UK) and water to provide 0.5 g carbohydrate/kg body mass. These were cooked in 171 
a microwave for 2 min at 1000 W, prior to a 5-min cooling period before serving. On CAL 172 
trials, a milk-extracted calcium powder (Capolac®, Arla Foods Ingredients amba, Denmark; 173 
from the same batch that has previously been independently validated (18)) was added to the 174 
porridge to increase the calcium content by 15 mg/kg body mass. On PRO trials, milk protein 175 
concentrate (MyProtein.co.uk, Northwich, UK) was added to increase the protein content of 176 
the porridge by 0.35 g/kg body mass. To test the synergy of protein and calcium, the 177 
PROCAL preload comprised of the addition of protein and calcium in identical absolute 178 
quantities to PRO and CAL trials (Table 2). The calcium concentration of the drinking water 179 
used to make the porridge was determined in duplicate using a photometric technique 180 
(Modular P, Roche Diagnostics Ltd., West Sussex, UK). This was determined as 0.82 ± 0.01 181 
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mmol/L (given an atomic mass of 40.078 g/mol this equates to 3.27 ± 0.03 mg/dl), and was 182 
taken into account in the calcium content of the preloads (Table 2). 183 
 184 
Anthropometric variables 185 
Body mass was determined to the nearest 0.1 kg using balance scales (Seca, Birmingham, 186 
UK) upon arrival at the laboratory, where participants wore only light clothing. Stature was 187 
measured to the nearest 0.1 cm using a stadiometer (Seca, Birmingham, UK). 188 
 189 
Subjective ratings 190 
Subjective appetite ratings were assessed using previously validated, 100 mm VAS (19), 191 
upon arrival at the laboratory (in the fasted, resting state). Questions asked included: “how 192 
hungry do you feel?”, “how full do you feel?”, “how satisfied do you feel?” and “how much 193 
do you think you can eat?”. These were also converted into a composite appetite score (which 194 
combines hunger, fullness, satisfaction and prospective consumption to provide a single 195 
value) as used previously (20). 196 
 197 
Blood sampling and analysis 198 
Blood samples were collected into EDTA tubes with 25 μL of aprotinin per mL of whole 199 
blood and were immediately centrifuged (10 min, 1509 g, 4°C). Aliquots of plasma were 200 
stored at -80°C before analysis. Plasma was analysed for insulin (IBL International GmbH, 201 
Hamburg, Germany), GIP1-42 (Immuno-Biological Laboratories Co., Ltd, Japan) and GLP-17-202 
36 concentrations (MesoScale Discovery, Maryland, USA), using commercially-available kits. 203 
Samples from all trials for each individual participant were always included on the same plate 204 
to minimise variation. Intra-assay coefficients of variation were below 10%. 205 
 206 
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Statistical analysis 207 
Due to difficulties with blood sampling from one participant, data for all blood variables are n 208 
= 19. Where data for a single timepoint during a individual’s trial was missing [11 points 209 
were missing out of a total of 380 (< 3%) for each blood-based variable], the linear 210 
interpolation was used to complete the data set. For clarity and to account for the additional 211 
energy in the high protein trials (whilst the calcium contained negligible additional energy), 212 
energy intake is reported as both absolute values (intake at the test meal only kJ) and energy 213 
compensation (%) calculated as follows: 214 
Energy compensation = (EICON/EIEXP+ΔEP)*100 215 
Where EI represents ad libitum energy intake following the control (EICON) or experimental 216 
(EIEXP) preloads and ΔEP represents the additional energy (above control) provided by the 217 
experimental preload. Energy compensation was calculated for PRO, CAL and PROCAL 218 
trials, with CON as the reference and data for energy compensation are reported at mean ± 219 
95% confidence intervals (95% CI), thus if the 95% CI do not overlap with 100, then there 220 
was significant under- or over-compensation. 221 
Plasma variables and subjective ratings were converted into time-averaged 222 
postprandial area under the curve (AUC) values. Data are expressed as mean ± standard error 223 
of the mean (SEM) for absolute data, whereas 95% confidence intervals (95% CI) are 224 
presented for mean differences relative to CON (i.e. PRO-CON, CAL-CON and PROCAL-225 
CON) and were analysed using Prism v5 (GraphPad Software, Dan Diego, CA). Data were 226 
checked for normal distribution using the Shapiro-Wilk normality test and were log-227 
transformed if appropriate, prior to statistical analysis. Male vs. female participant 228 
characteristics were compared by independent Student’s t tests. Two-way (trial x time) 229 
repeated-measures ANOVA were used to detect differences between plasma and appetite 230 
variables over time. A one-way ANOVA was used to detect differences between all trials 231 
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(CON vs. PRO vs. CAL vs. PROCAL) in energy intake, energy compensation, AUC data and 232 
to compare the mean differences of each trial relative to the control trial (PRO-CON vs. 233 
CAL-CON vs. PROCAL-CON). After a significant effect, post-hoc tests, adjusted for 234 
multiple comparisons (Holm-Sidak) were used to determine the location of variance. 235 
Differences were considered significant at P < 0.05. Associations between variables 236 
[expressed as the change relative to the CON trial (ΔCON)] were assessed by Pearson 237 
product-moment correlation coefficients. 238 
 239 
RESULTS 240 
Energy intake 241 
Repeated measures ANOVA detected a significant effect for energy intake at the test-meal (P 242 
< 0.05). Following adjustment for multiple comparisons, energy intake after PROCAL (3419 243 
± 345 kJ; P < 0.05) was significantly less than after CON (4126 ± 395 kJ), but not after PRO 244 
(3699 ± 304 kJ; P > 0.05) or CAL (3501 ± 253 kJ; P > 0.05). 245 
 Energy compensation was significantly greater (overcompensation) with CAL vs. 246 
PRO (Figure 1; P < 0.01) and tended to be greater with PROCAL vs PRO (P = 0.06). PRO 247 
produced almost perfect compensation (perfect compensation = 100%), whilst participants 248 
overcompensated following CAL (Figure 1). 249 
 250 
Subjective appetite sensations 251 
Two-way repeated measures ANOVA revealed a significant main effect of time for all 252 
subjective appetite variables (all P < 0.001). With regards to the composite appetite score, the 253 
main effect of trial was not significant (P > 0.05). There was however, a significant trial x 254 
time interaction effect (P < 0.05), whereby, following adjustment for multiple comparisons, 255 
PROCAL was lower than CON at 45 min post-preload (Figure 2A).  256 
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For all other appetite variables, there was no significant main effect of trial detected 257 
(all P > 0.05). Hunger, fullness, satisfaction and prospective consumption all displayed 258 
significant interaction (trial x time) effects (all P < 0.05; Supplemental Figure 1).  259 
Repeated measures ANOVA revealed a significant effect for the composite appetite 260 
AUC (P < 0.05), whereby PROCAL was lower than CON (Figure 2B). The hunger AUC 261 
displayed a significant overall effect (P < 0.05), although following adjustment for multiple 262 
comparisons, there were no significant difference detected between specific trials (all P > 263 
0.05). There was no overall effect for satisfaction or prospective consumption AUC (both P > 264 
0.05), although the main effect for fullness AUC approached significance (P = 0.06). 265 
When expressed as the change in appetite sensations relative to control (mean 266 
difference ± 95% CI; Figure 2C), PRO did not suppress appetite sensations (-3 mm, 95% CI: 267 
-8 to 3; P > 0.05), whereas the reduction with CAL vs. CON (-5 mm, 95% CI: -9 to 0; P = 268 
0.06) approached significance, and PROCAL significantly reduced the composite appetite 269 
AUC relative to CON (-5 mm, 95% CI: -10 to -1; P = 0.023). However, no significant 270 
differences were observed between PRO-CON vs. CAL-CON vs. PROCAL-CON (main 271 
effect: P > 0.05).  272 
 273 
Plasma variables 274 
Plasma insulin concentrations displayed a main effect of trial (P < 0.01) and a main effect of 275 
time (P < 0.001), with no significant interaction (trial x time) effect (P > 0.05; Figure 3A). 276 
Plasma GIP1-42 concentrations also demonstrated a main effect of trial (P < 0.01) and a main 277 
effect of time (P < 0.001), with no significant interaction effect detected (P > 0.05; Figure 278 
3B). Likewise, plasma GLP-17-36 concentrations displayed main effects of trial (P < 0.001) 279 
and time (P < 0.001) with no significant interaction effect (P > 0.05; Figure 3C). 280 
Page 13 
Repeated measures ANOVA revealed a significant overall effect for insulin, GIP1-42 281 
and GLP-17-36 AUC (P < 0.01, P < 0.05 and P < 0.001, respectively). Following adjustment 282 
for multiple comparisons, the insulin AUC was higher with PROCAL vs. CON 283 
(Supplemental Figure 3A). The GIP1-42 AUC was not significantly different between each 284 
trial (Supplemental Figure 3B), whilst the GLP-17-36 AUC was higher with PRO and 285 
PROCAL vs. CON (Supplemental Figure 3C). 286 
There were no differences between PRO, CAL and PROCAL in the change in insulin 287 
AUC relative to CON (Figure 4A), however, PRO and PROCAL produced significantly more 288 
positive changes relative to CON, when compared to CAL (Figure 4B and 4C). 289 
 290 
Associations between variables 291 
The only correlations that were statistically significant were for the ΔCON composite 292 
appetite score AUC vs. ΔCON energy intake (r = 0.37, P < 0.05; Supplemental Figure 2A),  293 
ΔCON plasma GIP1-42 AUC vs. ΔCON plasma GLP-17-36 AUC (r = 0.46, P < 0.001; 294 
Supplemental Figure 2B) and ΔCON composite appetite score AUC and ΔCON plasma GLP-295 
17-36 AUC (r = -0.35, P < 0.05; Supplemental Figure 2C). Estimated habitual calcium intake 296 
(range: 253-2700 mg/d; median: 973 mg/d) did not correlate with either ΔCON plasma GIP1-297 
42 AUC or ΔCON plasma GLP-17-36 AUC (r = -0.04, P > 0.05 and r = -0.02, P > 0.05, 298 
respectively). 299 
 300 
DISCUSSION 301 
Here we demonstrate that a high-protein preload produces almost perfect energy 302 
compensation, whilst a high-calcium preload (with and without protein) reduces appetite and 303 
results in overcompensation of subsequent energy intake (i.e. less energy intake relative to 304 
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the energy in the preload). This coincided with an elevation in insulinaemia, which could not 305 
be clearly attributed to responses of the incretin hormones GIP1-42 and GLP-17-36.  306 
 Previous evidence has suggested that dietary calcium may play a role in appetite 307 
control (6). However, the self-report nature of the measures used, combined with 308 
contradictory evidence (9, 21), make this somewhat equivocal. The data in the present study, 309 
acquired from a laboratory setting suggest that calcium, has the potential to acutely reduce 310 
postprandial appetite sensations and subsequent energy intake to a sufficient degree to offset 311 
any additional energy provided by the preload. Energy compensation was almost perfect (i.e. 312 
~100%) in the PRO trial, whereas significant overcompensation occurred with CAL and 313 
tended to occur with PROCAL (Figure 1B). These data are consistent with the subjective 314 
appetite responses observed (Figure 2C), whereby PROCAL lowered appetite relative to 315 
control and CAL tended to lower appetite, relative to CON. 316 
The lack of any detectable increase in incretin hormone concentrations with protein-317 
calcium co-ingestion could be due to either the habitual calcium intake of the participants, or 318 
the blood-sampling site. A double-blind, placebo-controlled study has demonstrated that 3 319 
weeks of calcium supplementation (1000 mg/d) results in a potentiation in postprandial 320 
plasma GLP-17-36 concentrations in response to a high-calcium meal, relative to a low-321 
calcium control meal (22). This effect was not seen after 3 weeks of placebo 322 
supplementation. Therefore, a high-habitual calcium intake may be required to observe an 323 
acute effect of calcium intake on plasma incretin hormones. We attempted to explore this in 324 
the present study by examining the association between self-reported habitual calcium intake 325 
and the change in plasma incretin concentrations with PROCAL vs. CON. No significant 326 
correlation was observed between either GIP1-42 or GLP-17-36, and habitual calcium intake. 327 
Although the limitations associated with food frequency questionnaires make it difficult to 328 
draw firm conclusions from these observations.  329 
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 With regard to the sampling site, veins in the antecubital fossa may not provide a 330 
representation of the major site of action. As previously mentioned, GIP1-42 and GLP-17-36 are 331 
secreted by enteroendocrine cells in the gastrointestinal tract. DPP-IV in the endothelium acts 332 
immediately, reducing the quantity of GLP-17-36 entering the hepatic circulation by 333 
approximately 75% from that which is originally secreted (10). Upon passing through the 334 
liver, degredation leaves 10-15% to enter the systemic circulation (10), where further 335 
degredation by DPP-IV in plasma and secreted by adipose tissue can take place (23). It is 336 
postulated that GLP-17-36 may be able to activate neurons in the intestine and liver (10), 337 
which permits central effects (on appetite and insulin secretion) independent of the systemic 338 
circulating concentration. Thus, to what degree the concentration measured in an antecubital 339 
vein reflects that in the enterocyte and hepatoportal region, which may be the sites of most 340 
interest, is unclear.   341 
 In addition, it should also be acknowledged that numerous other putative mechanisms 342 
may also contribute to the appetite effects of protein and calcium intake, including delayed 343 
gastric emptying (24), plasma amino acid concentrations (25), and the concentrations of other 344 
other gastrointestinal hormones such as cholecystokinin (26), peptide YY (12) and gastrin 345 
(27). Notwithstanding this, we chose to concentrate on the incretin hormones given the 346 
insulin responses previously observed in humans (7, 8, 18) and in vitro/ex vivo [11, 12]. 347 
The design and timing of the preload prior to energy intake assessment (1 h), was 348 
chosen based on previous observations that calcium intake displays a time-dependent 349 
suppressant effect on appetite sensations in this period (7, 8) and also due to this time period 350 
typically producing close to 100% compensation with preload designs (28) and is validated 351 
somewhat by the almost 100% compensation seen in the PRO trial. This does however, 352 
constrain the applicability of the findings to this time period, and extrapolation to longer time 353 
periods are not recommended without further research. In addition, the quantity of calcium 354 
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and provided in preloads is equivalent to ~800 ml milk. Therefore the practical application of 355 
these findings currently lies in fortification, rather than with normal milk composition. 356 
Nonetheless, this does provide a proof-of-principle and may be used to augment the satiety 357 
effects of pre-meal high-protein snacks (29, 30) and a dose-response study would be a logical 358 
progression. The primary outcome was determined as energy intake at the test-meal, 359 
however, PRO and PROCAL preloads also contained additional energy (Table 2), which 360 
means that any subsequent reduction in energy intake should be interpreted as appropriate 361 
energy compensation rather than a reduction per se.  362 
 In conclusion, the consumption on a preload containing additional protein results in 363 
almost perfect energy compensation, whilst the addition of calcium, with or without protein, 364 
suppresses appetite and energy intake such that overcompensation ensues with no apparent 365 
protein-calcium synergy.  It remains unclear whether these responses are attributable to 366 
changes in plasma insulin, GIP1-42 or GLP-17-36 concentrations. 367 
 368 
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Table 1 Participant characteristics and fasting plasma variables1 
 Total  
(n = 20) 
Males  
(n = 13) 
Females  
(n = 7) 
P value2 
Characteristics     
Age (y) 23 ± 1 24 ± 1 22 ± 1 0.15 
Body mass (kg) 71.0 ± 2.4 77.4 ± 1.7 59.0 ± 2.4 < 0.001 
Height (cm) 175 ± 2 180 ± 2 164 ± 2 < 0.001 
BMI (kg/m2) 23.2 ± 0.6 23.9 ± 0.7 21.9 ± 1.1 0.11 
Habitual calcium intake (mg/d) 1000 ± 126 1080 ± 169 855 ± 180 0.41 
Fasting plasma variables3,4     
Insulin (pmol/L) 91 ± 8 79 ± 9 112 ± 14 0.049 
GIP1-42 (pmol/L)
5 2.1 ± 0.3 2.4 ± 0.4 1.7 ± 0.3 0.25 
GLP-17-36 (pmol/L)
5 0.41 ± 0.08 1.58 ± 0.40 0.99 ± 0.28 0.32 
1All values are means ± SEM. 
2Male vs female, compared by independent Student’s t test. 
3Mean of 4 visits. 
4For blood variables n = 12 for males, and 7 for females. 
5GIP1-42, glucose-dependent insulinotropic polypeptide1-42; GLP-17-36, glucagon-like peptide-
17-36.
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Table 2 Nutritional composition of the preloads1,2 
 CON PRO CAL PROCAL 
Energy (kJ) 773 ± 27 1244 ± 43 783 ± 27 1253 ± 43 
Energy (kcal) 185 ± 6 297 ± 10 187 ± 6 299 ± 10 
Carbohydrate (g) 36 ± 1 37 ± 1 36 ± 1 38 ± 1 
Fat (g) 3 ± 0 4 ± 0 4 ± 0 4 ± 0 
Protein (g) 4 ± 0 29 ± 1 5 ± 0 29 ± 1 
Calcium (mg) 104 ± 4 104 ± 4 1170 ± 40 1170 ± 40 
Energy Density 
(kJ/g) 
2.1 ± 0.0 3.1 ± 0.0 2.1 ± 0.0 3.1 ± 0.0 
1All values are means ± SEM. 
2CAL, high-calcium; CON, control; PRO, high-protein;; PROCAL, high-protein and high-
calcium. 
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FIGURE 1. Energy compensation (%) during an ad libitum test meal 1 h following CON, 
PRO, CAL, or PROCAL preloads, in humans. Values are individual differences (circles) and 
means ± 95% confidence intervals (horizontal lines); n = 20. Labelled means without a 
common letter differ (P < 0.05). CAL, high-calcium; CON, control; PRO, high-protein; 
PROCAL, high-protein and high-calcium. 
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FIGURE 2. The composite appetite score following CON), PRO, CAL, or PROCAL 
preloads, in humans expressed over time (A), as a postprandial time-averaged (60 min) area 
under the curve (AUC; B) or as the mean difference ± 95% confidence intervals (horizontal 
lines; circles are individual data) between PRO, CAL and PROCAL, relative to CON (C); n = 
20. Values in A and B are means ± SEM. CON, control; PRO, high-protein; CAL, high-
calcium; PROCAL, high-protein and high-calcium; Labelled means without a common letter 
differ (P < 0.05). CAL, high-calcium; CON, control; PRO, high-protein; PROCAL, high-
protein and high-calcium. 
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FIGURE 3. Plasma insulin (A), GIP1-42, and GLP-17-36 concentrations following CON, PRO, 
CAL, or PROCAL preloads, in humans. Values are means ± SEM; n = 19. CAL, high-
calcium; CON, control; GIP1-42, glucose-dependent insulinotropic polypeptide1-42; GLP-17-36, 
glucagon-like peptide-17-36; PRO, high-protein; PROCAL, high-protein and high-calcium. 
  
Page 26 
FIGURE 4. Plasma insulin (A), GIP1-42, and GLP-17-36 postprandial time-averaged (60 min) 
area under the curve (AUC) following CON, PRO, CAL, or PROCAL preloads, in humans. 
Values are individual differences (circles) and mean difference ± 95% confidence intervals 
(horizontal lines) between PRO, CAL and PROCAL, relative to CON; n = 19. Labelled 
means without a common letter differ (P < 0.05). CAL, high-calcium; CON, control; GIP1-
42, glucose-dependent insulinotropic polypeptide1-42; GLP-17-36, glucagon-like peptide-17-36; 
PRO, high-protein; PROCAL, high-protein and high-calcium. 
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ONLINE SUPPORTING MATERIAL 
SUPPLEMENTAL FIGURE 1. Hunger (A), fullness (B), satisfaction (C) and 
prospective consumption (D) ratings following control (CON), high-protein (PRO), 
high-calcium (CAL), or high-protein and high-calcium (PROCAL) preloads, in 
humans. Values are means ± SEM; n = 20. *Different from CON (P < 0.05). 
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SUPPLEMENTAL FIGURE 2. Correlations between the composite appetite score 
postprandial area under the curve (AUC) and energy intake (A), plasma GLP-17-36 
AUC and GIP1-42 AUC (B), and GLP-17-36 AUC and the composite appetite score 
AUC. Data are expressed as the difference from the control trial (ΔCON); n = 20 for 
A, n = 19 for B and C. GIP1-42, glucose-dependent insulinotropic polypeptide1-42; 
GLP-17-36, glucagon-like peptide-17-36.
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SUPPLEMENTAL FIGURE 3. Plasma insulin (A), GIP1-42, and GLP-17-36 
postprandial time-averaged (60 min) area under the curve (AUC following control 
(CON), high-protein (PRO), high-calcium (CAL), or high-protein and high-calcium 
(PROCAL) preloads, in humans. Values are means ± SEM; n = 19. GIP1-42, 
glucose-dependent insulinotropic polypeptide1-42; GLP-17-36, glucagon-like peptide-
17-36; Labelled means  (P < 0.05). 
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